KOL Insight: Haemophilia A 2020

Maximum Purchase:
1 unit
Publication Date:
May 2020
Licence Type:
Multi-user licence
Adding to cart… The item has been added

Therapy Trends KOL Insight: Haemophilia A

As Roche's Hemlibra continues to advance as the go-to-drug for HA patients what are the prospects for pipeline products? What are KOLs' concerns with potentially transformative gene therapies such as Biomarin's Valrox and Sangamo/Pfizer's giroctocogene fitelparvovec? Will lingering safety issues hamper Alnylam/Sanofi's promising siRNA oligonucleotide fitsurin? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk

Key questions answered

  • Why are European physicians not using Roche's Hemlibra in the non-inhibitor segment as much as their US colleagues?
  • Why do experts think the combination of low-dose FVIIIs in conjunction with Hemlibra could be an attractive strategy?
  • What role do KOLs see for emergent rFVIIa therapies such as rEVO Biologics/LFB's Sevenfact?
  • Is there a future for anti-TFPI targeting mAbs?
  • Why are KOLs excited by ApcinteX's endogenous inhibitor of activated protein C, SerpinPC?

Examples of Therapies Covered

Hemlibra Elocta/Eloctate
Afstyla Esperoct
NovoEight Adynovate
Nuwiq Xyntha
BIVV 001 BAY 1093884
Giroctocogene fitelparvovec Advate/Kogenate

Partial List of Participating KOLs

  • Professor of Medicine
    Tulane University School of Medicine, New Orleans, LA.
  • Professor of Haemostasis and Thrombosis
    Hôpital Louis Pradel, University Claude Bernard Lyon 1, Bron, France.
  • Professor of Medicine and Pathology, Director of the Comprehensive Hemophilia and Thrombophilia Treatment Center
    Georgetown University, Washington, DC.
  • Professor of Haemostasis and Thrombosis
    Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, UK.
  • Professor of Hemostasis and Thrombosis, Division of Pediatric Hematology/Oncology
    Carmen and Ann Adams Department of Pediatrics, Children's Hospital of Michigan, Detroit, MI.
  • Member of the Medical Advisory Board of the World Federation of Hemophilia (WFH) and former President of Italian Association of Haemophilia Centres (AICE)
    Via Pace 9, Milan, Italy
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Job Title*
Company Name *
Country Name *
Job Function
Account Owner